-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

636.O1.6 636. Myelodysplastic Syndromes—Basic and Translational: Clonal Trajectories and Novel Therapies

Symposia: Myelodysplastic Syndromes—Basic and Translational Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Biological therapies, Acquired Marrow Failure Syndromes, Acute Myeloid Malignancies, AML, Fundamental Science, Translational Research, CHIP, Bone Marrow Failure Syndromes, elderly, genomics, Combination therapy, hematopoiesis, Chronic Myeloid Malignancies, CMML, Diseases, Therapies, computational biology, Biological Processes, Myeloid Malignancies, Technology and Procedures, gene editing, molecular biology, profiling, Human, pathogenesis, machine learning, omics technologies
Saturday, December 10, 2022: 9:30 AM-11:00 AM
260-262 (Ernest N. Morial Convention Center)
Moderators:
Kathy L McGraw, Ph.D., National Cancer Institute and Aditi Shastri, MD, Hematology/Oncology, Montefiore Medical Center/Albert Einstein College of Medicine
Disclosures:
No relevant conflicts of interest to declare.
The oral session focuses on the clonal trajectories and therapeutic targeting based on clinical and basic research on MDS.
9:30 AM

Hideki Makishima, MD, PhD1, Ryunosuke Saiki2*, Yasuhito Nannya, M.D., Ph.D.2,3, Sophia C. Korotev4*, Carmelo Gurnari, MD5,6, June Takeda, MD1*, Yukihide Momozawa, DVM, Ph.D7*, Steve Best, PhD8*, Pramila Krishnamurthy, MD9*, Tetsuichi Yoshizato, MD, PhD2,10, Yoshiko Atsuta11,12*, Yusuke Shiozawa, MD, PhD13,14*, Yuka Iijima-Yamashita, PhD15*, Kenichi Yoshida2,16, Yuichi Shiraishi, PhD17*, Yasunobu Nagata, MD, PhD2*, Nobuyuki Kakiuchi, MD, PhD2*, Makoto Onizuka, MD, PhD18, Kenichi Chiba, PhD19*, Hiroko Tanaka, B.A.20*, Ayana Kon, MD, PhD2*, Yotaro Ochi, MD, PhD21*, Masahiro Marshall Nakagawa, MD, PhD2, Rurika Okuda, MSc, BS13*, Takuto Mori, MD2*, Akinori Yoda, PhD13*, Hidehiro Itonaga, MD, PhD22, Yasushi Miyazaki, MD23, Masashi Sanada, MD, PhD15, Takayuki Ishikawa24, Shigeru Chiba, MD, PhD25, Hisashi Tsurumi, MD, PhD26, Senji Kasahara27, Carsten Müller-Tidow, MD28*, Akifumi Takaori-Kondo, MD, PhD29, Kazuma Ohyashiki, MD, PhD30, Toru Kiguchi, MD, PhD31*, Fumihiko Matsuda, MD, PhD32*, Joop H. Jansen, PhD33, Chantana Polprasert, MD34*, Piers Blombery, MBBS35, Yoichiro Kamatani, MD, Ph.D36*, Satoru Miyano, PhD20*, Luca Malcovati, MD37, Torsten Haferlach, MD38, Michiaki Kubo, MD, Ph.D39*, Mario Cazzola, MD40, Austin Kulasekararaj, MD, MBBS, FRCPath, MRCP41, Lucy A. Godley, MD, PhD42, Jaroslaw P. Maciejewski, MD, PhD, FACP43 and Seishi Ogawa, MD, PhD10,13,44

1Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, KYO, Japan
2Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
3Department of Hematology/Oncology, IMSUT Hospital, The University of Tokyo, Tokyo, Japan
4Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
5Department of Biomedicine and Prevention, Ph.D. in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy
6Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
7Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
8King's College Hospital, London, United Kingdom
9King's College Hospital NHS Foundation Trust, London, United Kingdom
10Center for Hematology and Regenerative Medicine, Department of Medicine (MedH), Karolinska Institutet, Huddinge, Sweden
11The Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan
12Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan
13Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto City, Japan
14Department of Biochemistry and Molecular Biology, Nippon Medical School, Tokyo, Japan
15Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
16Wellcome Trust Sanger Institute, Hinxton, United Kingdom
17Laboratory of Sequence Data Analysis, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
18Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan
19Center for Cancer Genomics and Advanced Therapeutics, National Cancer Center Research Institute, Tokyo, Japan
20M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan
21Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, HYO, Japan
22Department of Hematology, Nagasaki University Hospital, Nagasaki city, NSK, Japan
23Department of Hematology, Atomic Bomb Disease Institute, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan
24Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan
25Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
26Hematology, Gifu University Graduate School of Medicine, Gifu, Japan
27Department of Hematology, Gifu Pharmaceutical University, Gifu, Japan
28Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
29Department of Hematology, Kyoto University, Kyoto, Japan
30Department of Advanced Cellular Therapy, Tokyo Medical University, Tokyo, Japan
31Department of Hematology, Chugoku Central Hospital, Fukuyama, HIR, Japan
32Kyoto University Graduate School of Medicine, Kyoto, JPN
33Radboud Institute Molecular Studies, Radboud University Medical Center, Nijmegen, Netherlands
34Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand
35Peter MacCallum Cancer Centre, Peter Maccallum Cancer Centre, East Melbourne, VIC, Australia
36Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
37Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Pavia, Italy
38MLL Munich Leukemia Laboratory, Munich, Germany
39Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
40University of Pavia, University of Pavia, Pavia, Italy
41King’s College Hospital, National Institute for Health and Care Research/Wellcome King’s Clinical Research Facility, London, ENG, United Kingdom
42University of Chicago Medical Center, Chicago, IL
43Translational Hematology and Oncology Research, Cleveland Clinic Foundation/ Taussig Cancer Institute, Cleveland, OH
44Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan

9:45 AM

Martina Sarchi, MD1,2*, Courtnee A Clough, Ph.D1,3, Anna Gallì, PhD4*, Gabriele Todisco, MD2*, J. Philip Creamer, PhD1*, Luca Malcovati, MD2,4 and Sergei Doulatov, PhD1,5,6

1Division of Hematology, University of Washington, Seattle, WA
2Department of Molecular Medicine, University of Pavia, Pavia, Italy
3Molecular and Cellular Biology Program, University of Washington, Seattle, WA
4Department of Hematology Oncology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy
5Department of Genome Sciences, University of Washington, Seattle, WA
6Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA

10:00 AM

Kristian Gurashi1*, Yu-Hung Wang, MD1,2*, Tim C.P Somervaille, PhD FRCP FRCPath3,4, Kiran Batta, PhD1* and Daniel H Wiseman, PhD, MB, ChB, MRCP, FRCPath1,5*

1Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom
2Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
3Haematology Department, The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
4Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom
5Haematology, The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom

10:15 AM

David Rombaut1,2,3*, Carine Lefevre, PhD1,4*, Batoul Farhat, PhD1,2*, Sabrina Bondu, PharmD, PhD1*, Anne Letessier, PhD1*, Auriane Lesieur-Pasquier, PharmD1,2*, Daisy Castillo-Guzman, PhD5*, Marjorie Leduc, PhD6*, Emilie-Fleur Gautier, PhD6*, Virginie Chesnais, PhD1*, Alice Rousseau1*, Ismael Boussaid, PharmD, PhD1,2*, Sarah Battault1,2*, Alexandre Houy7*, Didier Bouscary, MD, PhD1,8*, Lise Willems, MD, PhD1,8*, Nicolas Chapuis, PharmD, PhD1,9*, Sophie Park, MD, PhD10, Sophie Raynaud, MD, PhD11*, Thomas Cluzeau, MD, PhD12, Emmanuelle Clappier, PharmD, PhD13*, Pierre Fenaux14, Lionel Ades15, Eric Solary, MD PhD16, Raphael Margueron, PhD17*, Michel Wassef, PhD17*, Olivier Kosmider, MD, PhD1,9*, Samar Alsafadi, PhD7*, Nathalie Droin, PhD18*, Angelos Constantinou, PhD19*, Marc-Henri Stern, MD, PhD7*, Benoit Miotto, PhD1*, Frederic Chedin, PhD5* and Michaela Fontenay, MD, PhD1,2,3,9

1Université Paris Cité, CNRS, INSERM U1016, Institut Cochin, Paris, France
2Equipe Labellisée Fondation pour la Recherche Médicale, Paris, France
3Laboratoire d'Excellence du Globule Rouge, GR-Ex, Paris, France
4Laboratoire d'excellence du Globule Rouge, GR-Ex, Université Paris Cité, Paris, France
5Department of Molecular and Cellular Biology and Genome Center, University of California, Davis, CA
6Platform Proteom'IC, Université Paris Cité, CNRS, INSERM U1016, Institut Cochin, Paris, France
7Institut Curie, PSL Research University, Sorbonne University, INSERM U830, DNA repair and uveal melanoma, Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France
8Assistance Publique-Hôpitaux de Paris.Centre-Université Paris Cité, Hôpital Cochin, Department of Hematology, Paris, France
9Assistance Publique-Hôpitaux de Paris.Centre-Université Paris Cité, Hôpital Cochin, Laboratory of Hematology, Paris, France
10Department of Clinical Hematology, Centre Hospitalo-Universitaire Grenoble Alpes, Grenoble, France
11Université Côte d'Azur, Centre Hospitalier Universitaire, Laboratory of Hematology, Nice, France
12Département d'Hématologie Clinique, Université Côte d'Azur, CHU Nice, Nice, Provence Alpes Cote d'Azur, France
13Hematology Laboratory, AP-HP, Hôpital Saint-Louis, Paris, France
14Service d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, Paris, France
15Department of Hematology, Université de Paris, Saint-Louis Hospital, Paris, France
16Université Paris-Saclay, INSERM U1287, Gustave Roussy Cancer Campus, Villejuif, France
17Institut Curie, Paris Sciences Lettres Research University, Sorbonne University, INSERM U934, UMR3215, Paris, France
18Université Paris Saclay, INSERM U1287, Gustave Roussy Cancer Campus, Villejuif, France
19Institut de Génétique Humaine, Centre National de la Recherche Scientifique, Université de Montpellier, Montpellier, France

10:30 AM

Sayantani Sinha, PhD1, Zhiyan Silvia Liu2*, Maxwell Bannister2*, Erica Arriaga-Gomez1*, Axia Song1*, Dawei Zong2*, Martina Sarchi, MD3,4,5*, Elizabeth Bonner1*, Victor Corral2*, Cassandra Leibson2*, Wannasiri Chiraphapphaiboon2*, Derek Stirewalt6, Joachim Deeg, MD7,8*, Sumit Rai, PhD9*, Matthew J Walter, MD10, Timothy A. Graubert, MD11, Sergei Doulatov, PhD12,13,14,15, Dang Hai Nguyen, PhD16,17 and Stanley C Lee, PhD1

1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
2Department of Pharmacology, University of Minnesota, Minneapolis, MN
3Division of Hematology, University of Washington, Seattle, WA
4Department of Molecular Medicine, University of Pavia, Pavia, ITA
5Department of Molecular Medicine, University of Pavia, Pavia, Italy
6Fred Hutchinson Cancer Center, Seattle
7Fred Hutchinson Cancer Center, Seattle, WA
8Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA
9Massachusetts General Hospital Cancer Center, Boston, MA
10Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO
11Massachusetts General Hospital Cancer Center, Charlestown, MA
12Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA
13University of Washington School of Medicine, Seattle, WA, USA, Seattle
14Department of Genome Sciences, University of Washington, Seattle, WA
15Division of Hematology, University of Washington School of Medicine, Seattle, WA
16Department of Pharmacology, Molecular and Cellular Biology Bldg, Minneapolis, MN
17Masonic Cancer Center, University of Minnesota, Minneapolis, MN

10:45 AM

Peter Truong1*, Sylvie Shen, MD, PhD2*, Swapna Joshi, MSc1*, Ali Afrasiabi, MSc3*, Ling Zhong, PhD4*, Mark J. Raftery, PhD4*, Jonas Larsson, MD, PhD5, Richard B. Lock, PhD6,7,8*, Carl R. Walkley, PhD9,10*, Hamid Alinejad Rokny, PhD3,11,12*, Julie A.I. Thoms13*, Christopher J. Jolly, PhD2* and John E. Pimanda, MBBS, FRACP, FRCPA, PhD1,2,14

1School of Clinical Medicine, University of New South Wales, Sydney, Australia
2School of Medical Sciences, University of New South Wales, Sydney, Australia
3BioMedical Machine Learning Lab, Graduate School of Biomedical Engineering, University of New South Wales, Sydney, Australia
4Bioanalytical Mass Spectrometry Facility, University of New South Wales, Sydney, Australia
5Division of Molecular Medicine and Gene Therapy, Lund Stem Cell Centre, Lund University, Lund, Sweden
6School of Women’s and Children’s Health, University of New South Wales, Sydney, Australia
7Children’s Cancer Institute, University of New South Wales, Sydney, Australia
8University of New South Wales Centre for Childhood Cancer Research, University of New South Wales, Sydney, Australia
9St. Vincent's Institute, University of Melbourne, Melbourne, Australia
10Department of Medicine, University of Melbourne, Melbourne, Australia
11UNSW Data Science Hub, University of New South Wales, Sydney, Australia
12Health Data Analytics Program, AI-Enabled Processes Research Centre, Macquarie University, Sydney, Australia
13School of Medical Sciences, University of New South Wales, Randwick, Australia
14Haematology Department, Prince of Wales Hospital, Sydney, Australia

*signifies non-member of ASH